Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

We'll know more about the company's medium-term prospects by the end of the year.

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year pipeline ...

The biotech sector has found its footing again after several difficult years. The equal-weighted S&P Biotechnology ETF (XBI) has staged an impressive rebound, helped by a revival in risk appetite, ...

Franklin Equity reported on February 16 that, following a protracted period of uncertainty in the previous year, the ...